IGXT Stock News 0.7850 05/07/2014 01:05:45 Intelgenx Technologs

New Post Public Reply Private Reply Replies (0) Message Board

May 7, 2014 at 2:05 AM

Intelgenx Technologs (IGXT) 0.7850 $IGXT

IntelGenx Announces Government of Canada Funding for CNS VersaFilm(TM) Project
GlobeNewswire - Wed Apr 30, 7:14AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"

, a Canadian drug delivery company focusing on oral drug delivery, today announced financial support from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). In addition to advisory services and technological expertise, the funding provided by NRC-IRAP will support further development of a product for the treatment of central nervous system (CNS) diseases and disorders. The product will be based upon IntelGenx' proprietary, oral thin film, VersaFilm(TM), technology.

IntelGenx and RedHill Biopharma Announce Commencement of a Bioavailability Study with Anti-Migraine VersaFilm(TM) Product to Support European Marketing Application Planned for Q3/2014
Newsfile Corp - Mon Apr 28, 7:06AM CDT
full story)

RedHill Biopharma and IntelGenx Announce Commencement of a Bioavailability Study With RHB-103 (Migraine) to Support European Marketing Application Planned for Q3/2014
GlobeNewswire - Mon Apr 28, 7:01AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"

, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, together with IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx"

, a Canadian drug delivery company focused on oral drug delivery, today announced the commencement of a comparative bioavailability clinical study comparing RHB-103 to the European reference drug. The study is intended to support the planned submission of a European Marketing Authorization Application ("MAA"

for RHB-103, a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines.

CytoSorbents Corp. Expands Its Product Distribution to Include the Middle East
ACCESSWIRE - Fri Apr 25, 8:51AM CDT
CytoSorbents Corp.'s (OTCQB: CTSO) stock volume surged Apr. 24, with 1,774,353 shares changing hands, higher than its three-month average volume of 1,703,870 shares.

IntelGenx and RedHill Biopharma Provide an Update on FDA's Ongoing Review of the NDA for Migraine VersaFilm(TM) Product
GlobeNewswire - Thu Apr 24, 7:27AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX: IGXT) ("IntelGenx"

, a Canadian drug delivery company focusing on oral drug delivery, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"

, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, today reported that the U.S. Food and Drug Administration ("FDA"

acknowledged receipt of their response to the Complete Response Letter ("CRL"

for the VersaFilm(TM) Oral Film Product New Drug Application ("NDA"

and has requested further clarifications. The VersaFilm(TM) Oral Film Product is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines.

RedHill Biopharma and IntelGenx Provide an Update on FDA's Ongoing Review of the NDA for RHB-103 Oral Migraine Film
GlobeNewswire - Thu Apr 24, 7:00AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"

, a Canadian drug delivery company focusing on oral drug delivery, today reported that the U.S. Food and Drug Administration ("FDA"

acknowledged receipt of their response to the Complete Response Letter ("CRL"

for the RHB-103 New Drug Application ("NDA"

and has requested further clarifications. RHB-103 is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines.

IntelGenx Announces Receipt of an Additional U.S. Patent Allowance Related to Proprietary Technology
GlobeNewswire - Wed Apr 16, 7:15AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"

, a Canadian drug delivery company focusing on oral drug delivery, today announced that it has received a Notice of Allowance ("NOA"

from the United States Patent and Trademark Office ("USPTO"

for U.S. Patent Application Serial No. 12/836,810 entitled "Oral mucoadhesive dosage form" which covers IntelGenx' proprietary AdVersa(TM) mucoadhesive drug delivery technology. This NOA concludes the examination of the U.S. patent application and will result in the issuance of a U.S. patent after the administrative process is completed.

IntelGenx Reports 2013 Annual Results and Provides Corporate Development Update
GlobeNewswire - Tue Mar 11, 7:32AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (the "Company"

today announced financial results for its fiscal year ended December 31, 2013 and provided an update on operational developments. All amounts are in U.S. Dollars, unless otherwise stated.

IntelGenx and RedHill Biopharma Submit Response to FDA CRL for VersaFilm(TM) Product for Migraines
GlobeNewswire - Mon Mar 03, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"

, a Canadian drug delivery company focusing on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"

, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, that they submitted a response to the Complete Response Letter ("CRL"

of the U.S. Food and Drug Administration ("FDA"

for the New Drug Application ("NDA"

for their VersaFilm(TM) Oral Film Product for the treatment of acute migraines.

RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film
GlobeNewswire - Mon Mar 03, 7:00AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"

, an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage drugs, today announced, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"

, a Canadian drug delivery company focusing on oral drug delivery, that they submitted a response to the Complete Response Letter ("CRL"

of the U.S. Food and Drug Administration ("FDA"

for the New Drug Application ("NDA"

for RHB-103, an oral thin-film rizatriptan for the treatment of acute migraines.

IntelGenx Announces Receipt of Two Additional U.S. Patent Allowances Related to Proprietary Technology
GlobeNewswire - Wed Feb 26, 7:42AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"

, a Canadian drug delivery company focusing on oral drug delivery, today announced that it has received a Notice of Allowance ("NOA"

from the United States Patent and Trademark Office for U.S. Patent Application Serial No. 11/647,033 entitled "Multilayer tablet" which covers the technology used in our hypertension product currently under development. A second NOA has been received for U.S. Patent Application Serial No. 11/782,838 entitled "Controlled-release pharmaceutical tablets" which is related to the drug delivery technology used in Forfivo XL(R), IntelGenx' first FDA-approved product currently commercialized in the U.S. These two NOA's conclude the examination of each U.S. patent application and will result in the issuance of two U.S. patents after administrative processes are completed.

IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm(TM) Tadalafil Product
GlobeNewswire - Mon Feb 24, 7:08AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"

, a Canadian drug delivery company focusing on oral drug delivery, today announced the completion of a pilot biostudy with its proprietary VersaFilm(TM) tadalafil product for erectile dysfunction that indicated bioequivalence with the leading brand reference listed drug (RLD) tadalafil product.

IntelGenx Technologies Report Delivers Analyst Opinion and Fundamental Data
PR Newswire - Wed Feb 05, 6:00AM CST
NEW YORK, Feb. 5, 2014 /PRNewswire - IntelGenx Technologies Corp (OTC: IGXT), is a drug delivery company, that engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market.

IntelGenx and RedHill Biopharma Receive Complete Response Letter From FDA for VersaFilm(TM) Oral Film Product for Acute Migraines
GlobeNewswire - Tue Feb 04, 9:49PM CST
-- FDA's letter accepted the bioequivalence study and safety information submitted and requires no additional clinical studies; IntelGenx and RedHill plan to address remaining issues, primarily related to third party manufacturing, packaging and labeling, within weeks based on available data

11th Trust Dialogue - Impunity Number One Enemy of Democracy-Ekeweremadu
by Ronald Mutum - All Africa Global Media - Fri Jan 17, 1:21AM CST
The Deputy Senate President, Ike Ekeweremadu has said impunity in politics is the number one enemy of Nigeria's democracy.

IntelGenx Announces Additional Development and Commercialization Agreement With Par Pharmaceutical, Inc. for Two More Products
GlobeNewswire - Mon Jan 13, 7:05AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" or the "Company"

, a Canadian drug delivery company focusing on oral drug delivery, today announced that it has entered into another development and commercialization agreement with Par Pharmaceutical, Inc. ("Par"

for two new products utilizing IntelGenx' proprietary oral drug delivery platforms.

IntelGenx Grants Stock Options
GlobeNewswire - Thu Jan 09, 10:34AM CST
IntelGenx Technologies Corp. ("IntelGenx", or the "Company"

(TSX-V:IGX) (OTCQX:IGXT) announced today that the Company's board of directors granted options to acquire 120,000 common shares under the 2006 Stock Option Plan, as amended. The options were granted to the President and Chief Executive Officer, Dr. Rajiv Khosla in accordance with his employment agreement.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NOWINCLUDED Unfiltered: Podcasting's New Trailblazer

Signals of Change in Podcasting In a world of constant noise, finding a voice that cuts through the chatter is a rarity. Enter NOWINCLUDED Unfiltered, the podcast hosted by Tiffany Whitlow that's making waves for its unique approach to tackling some of healthcare's most pressing issues. This isn't your run-of-the-mill podcast. It's a no-holds-barred dive into health...

Epic Oceanside Estate Set for No-Reserve Luxury Auction

Going, Going, Gone? A Golf Exec's Dream Home What's hotter than Florida's summer sun? It's this swanky estate at Ponte Vedra Beach set to hit the auction block without any safety net. Yup, no reserve, folks! Leonard "Len" Brown, Jr., the brains behind many of PGA Tour's global ventures, has decided to put his lavish 3.2-acre plot right by the ocean up for grabs. Once...

Utopia Bagels Honored at 2026 New York BagelFest

From Queens Streets to Global Fame Try to picture this: a small neighborhood shop where the scent of freshly baked bagels wafts through, bringing together old friends and new generations. Now, take that local magic and multiply it by a global stage. That's the journey Utopia Bagels from Queens stepped into with massive strides over 45 years, earning a celebrated spot in...

Gentex Faces Investigation as Shares Tumble 7%

Investigating Gentex's Financial Setback Gentex Corporation, ticker NASDAQ:GNTX, is caught in a bit of a blizzard right now. Their shares took a nosedive, down 7%, after some messy numbers came out in their third-quarter report—tariffs and the kind of pricing pressure that makes grown investors wince. If you threw your chips in on Gentex and got burned, the lawyers are...

New PGCE Aims to Boost Confidence in Private Tutoring

Shifting the Landscape of Private Tutoring Here's a turn of events: parents now have a new tool at their disposal to vet private tutors. The recently unveiled PGCE Tutoring by UWE Bristol aims to provide an added layer of confidence for families navigating the private tutoring market. Breaking the Myth of Tutor Qualifications Did you know a whopping 54% of UK adults think...

OperaWine 2027 Spotlights Women-Led Italian Wineries

The Rise of Women's Leadership in Italian Winemaking If there’s anything that gets me up off the bench, it’s innovation in tradition. And that's just what Vinitaly OperaWine is doing in 2027. For the first time, they've carved out a special category, "Led by Women," featuring a lineup of 46 Italian wineries ran by women. These ladies are stepping into the limelight at...

Breaking Down Oklahoma's Car Insurance Costs

Understanding Car Insurance Dynamics in Oklahoma In the labyrinth of car insurance premiums, drivers in Oklahoma are left navigating a multitude of factors. A recent article from HelloNation, featuring insurance agent Bobby Williamson, dives into these elements with a candor that cuts through the fluff. Understanding what drives those numbers up or down isn't just for the...

Govee's Retro Holiday Lights: A Festive Nostalgia Trip

Ah, the holidays—they're creeping up like a kid sneaking downstairs for a peek at their gifts. But it's not the gifts under the tree that brighten a room, it's those lights draping the tree itself. Enter Govee, bringing us back to that vintage glow we all remember from our childhoods. They've teamed up with Brady Tolbert, a design whiz who can make a living room look...

Sands China's Latest Move: A Bond Offering Twist

Breaking Down Sands China's Bond Maneuver Today, we found out that Sands China is teeing up a fresh round of senior unsecured notes. Now, if that doesn't get your ticker flickin', maybe you're too used to market snoozefests. The folks at the helm of Sands China, a subsidiary under the mighty Las Vegas Sands Corp. (NYSE: LVS), are rolling out these USD-denominated notes...

PG&E Halts Service; Groups Demand Regulatory Action

Pending Storm Over PG&E's Service Delays It's rare that you hear a utility company flat-out say it can't afford to keep the lights on. Yet here we are, staring down the barrel of some unsettling news for 25,000 PG&E customers. They've been warned they might cool their heels for an extra six months before their service is up and running. As if that's not dicey enough, $2...